Company profile: MILabs
1.1 - Company Overview
Company description
- Provider of high-end molecular imaging solutions for biomedical research, including systems for quantitative 3D functional imaging of SPECT (U-SPECT) and PET (U-PET) tracers, an integrated PET/SPECT platform for simultaneous high-resolution imaging (VECTor), and automated quantitative 3D autoradiography of tissue samples with multiple isotopes (EXIRAD-3D).
Products and services
- VECTor: Multi-modal integrated PET/SPECT system enabling simultaneous imaging of PET and SPECT tracers with high spatial resolution for biomedical research applications
- U-SPECT: Small-animal system for quantitative 3D functional imaging of SPECT tracers, offering high resolution and fast imaging capabilities tailored to small animal studies in biomedical research
- U-PET: Quantitative system for 3D functional imaging of PET tracers, capable of high-resolution imaging and reducing image noise to enhance data quality in biomedical research
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MILabs
Abraxis BioScience
HQ: United States
Website
- Description: Provider of next-generation therapeutics and core technologies for the treatment of cancer and other critical illnesses; engages in the discovery, development, and delivery of therapies, including Abraxane, a nanoparticle chemotherapeutic compound.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abraxis BioScience company profile →
CC Bio
HQ: United Kingdom
Website
- Description: Provider of microbiome-focused therapeutic discovery for diagnosis and treatment. Products include Zeus, a platform to evaluate and optimize therapeutics for precise augmentation of microbial ecology; Athena, a platform developing genetic components for biosensor circuits that sense microbiome diseases; and Dionysus, a program engineering bacterial chassis to sense metabolic changes and record information across human tissues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CC Bio company profile →
Helapet
HQ: United Kingdom
Website
- Description: Provider of medical and cleanroom consumables as a manufacturer and distributor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Helapet company profile →
Hamilton Thorne
HQ: United States
Website
- Description: Provider of advanced laser systems and instruments for in-vitro cell applications in regenerative medicine research and fertility clinic markets. Offerings include ZILOS-tk and XYClone lasers that attach to inverted microscopes and act as robotic micro-surgeons; sperm analyzers and CASA platforms (IVOS II, TOX IVOS II), IVF equipment, and ZANDAIR PCOC3 in-duct air purification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hamilton Thorne company profile →
LumaCyte
HQ: United States
Website
- Description: Provider of label-free single-cell analysis solutions that accelerate medical discoveries, including Radiance, an instrument measuring cellular response using optical and fluidic forces; Laser Force Cytology technology; and software suites Illuminate for control/data analysis and ReportR for automated cloud reporting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LumaCyte company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MILabs
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MILabs
2.2 - Growth funds investing in similar companies to MILabs
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MILabs
4.2 - Public trading comparable groups for MILabs
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →